BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33186371)

  • 1. Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.
    Wang Q; Xu L; Wang G; Chen L; Li C; Jiang X; Gao H; Yang B; Tian W
    PLoS One; 2020; 15(11):e0241241. PubMed ID: 33186371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Beclin1 Expression and Nrf2 Overexpression are Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer.
    Yu S; Cheng C; Wang J; Wang J; Qu Z; Ren H; Li Y; Ning Q; Chen M; Hu T
    Anticancer Agents Med Chem; 2018; 18(12):1680-1687. PubMed ID: 30160218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High NF-E2-related factor 2 expression predicts poor prognosis in patients with lung cancer: a meta-analysis of cohort studies.
    Yang Q; Deng H; Xia H; Xu M; Pan G; Mao J; Tao S; Yamanaka K; An Y
    Free Radic Res; 2020 Dec; 54(11-12):790-798. PubMed ID: 31298052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
    Kim JH; Bogner PN; Ramnath N; Park Y; Yu J; Park YM
    Clin Cancer Res; 2007 Jul; 13(13):3875-82. PubMed ID: 17606720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer.
    Chen MJ; Lin PL; Wang L; Cheng YM; Chen CY; Lee H
    Thorac Cancer; 2020 Jul; 11(7):1904-1910. PubMed ID: 32394538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].
    Zhu X; Liang L; Liu C; Yin W; Chen S; Cao B
    Zhongguo Fei Ai Za Zhi; 2014 Feb; 17(2):155-62. PubMed ID: 24581168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.
    Liu X; Huang G; Zhang J; Zhang L; Liang Z
    PLoS One; 2020; 15(10):e0240321. PubMed ID: 33052949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer.
    Tong YH; Zhang B; Yan YY; Fan Y; Yu JW; Kong SS; Zhang D; Fang L; Su D; Lin NM
    Oncotarget; 2017 Jul; 8(28):45750-45758. PubMed ID: 28501854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
    Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
    Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles of Nrf2 signal in non-small cell lung cancer.
    Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K
    J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CXCR4 and Nrf2 expressions in non-small cell lung cancer and their clinical implications].
    Hu T; Yao Y; Yu S; Guo H; Tian T; Han L; Wang W; Guo Q; Wang J; Nan K; Wang S
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):153-8. PubMed ID: 24589587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic significance of NM23 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis.
    Min SH; Zheng QQ
    Medicine (Baltimore); 2021 Nov; 100(47):e27919. PubMed ID: 34964763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between 18F-FDG uptake in PET/CT, Nrf2, and NQO1 expression and their prognostic significance in non-small cell lung cancer.
    Park SY; Lee SJ; Han JH; Koh YW
    Neoplasma; 2019 Jul; 66(4):619-626. PubMed ID: 30868898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
    Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
    J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.